nimodipine has been researched along with Akinetic-Rigid Variant of Huntington Disease in 2 studies
Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Quinolinic acid (QA) is an endogenous excitotoxin present in mammalian brain that reproduces many of the histologic and neurochemical features of Huntington's disease (HD)." | 1.27 | Systemic approaches to modifying quinolinic acid striatal lesions in rats. ( Beal, MF; Ferrante, RJ; Kowall, NW; Martin, JB; Swartz, KJ, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Williams, A | 1 |
| Sarkar, S | 1 |
| Cuddon, P | 1 |
| Ttofi, EK | 1 |
| Saiki, S | 1 |
| Siddiqi, FH | 1 |
| Jahreiss, L | 1 |
| Fleming, A | 1 |
| Pask, D | 1 |
| Goldsmith, P | 1 |
| O'Kane, CJ | 1 |
| Floto, RA | 1 |
| Rubinsztein, DC | 1 |
| Beal, MF | 1 |
| Kowall, NW | 1 |
| Swartz, KJ | 1 |
| Ferrante, RJ | 1 |
| Martin, JB | 1 |
2 other studies available for nimodipine and Akinetic-Rigid Variant of Huntington Disease
| Article | Year |
|---|---|
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
Topics: Animals; Autophagy; Calcium Channels, L-Type; Clonidine; Cyclic AMP; Humans; Huntington Disease; Imi | 2008 |
Systemic approaches to modifying quinolinic acid striatal lesions in rats.
Topics: 2-Amino-5-phosphonovalerate; Allopurinol; Amino Acids; Animals; Antioxidants; Baclofen; Corpus Stria | 1988 |